Medtronic announced first-quarter FY25 financial results on Tuesday. Here are three things to know: 

A strong start      

Our innovative technologies fueled 5.3% organic revenue growth during the first quarter. Notable growth drivers included our Percept™ RC deep brain stimulator, transcatheter aortic heart valves (TAVR), and our MiniMed™ 780G automated insulin delivery (AID) system that treats diabetes.  

Innovating for the future 

We launched several therapies that will build on our momentum – and benefit patients. Those include Inceptiv™, an advancement in the treatment of chronic pain through spinal cord stimulation therapy, and Evolut™ FX+ TAVR, a therapy for patients with severe aortic stenosis. 

Raising our guidance 

Following our strong first-quarter performance, we’re raising our guidance for the full fiscal year. We now expect organic revenue growth of 4.5% to 5%, and non-GAAP diluted earnings per share of $5.42 to $5.50. 

L009-08192024

Related content

Technology bias is real. Here’s what we’re doing to fix it

An engineer and the earthworms that revolutionized spinal cord stimulation

Medtronic among America’s best companies for workplace fairness